Purchase this article with an account.
P. Grenga, M. Sepe, O. Verallo, A. La Capria, S. Fragiotta, A. Meduri, E. M. Vingolo; Functional and Morphological Analysis of Intravitreal Ranibuzumab Efficacy in Neovascular ARMD: Six-Months Follow-Up. Invest. Ophthalmol. Vis. Sci. 2010;51(13):5110.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To evaluate efficacy and correlate functional and morphological effects of intravitreal ranibizumab in neovascular age-related macular degeneration after recommended loading regimen.
20 eyes of 20 patients affected by neovascular age related macular degeneration received 3 intravitreal injections of 0.05 ml (0.5mg) ranibizumab in monthly intervals. All lesion type was included: classic, minimally classic and occult. Best Corrected Visual Acuity (BCVA), FA/ICG, Autofluorescence and SD OCT (Heidelberg Spectralis) and Microperimetry (MP-1, Nidek) were performed at baseline and 30 days after the third injection.
Treatment compliance was excellent with 100% of eyes receiving scheduled injections. Retinal function (BCVA and MP) increased significantly (p<0.01) after loading regimen, FA and SD OCT showed reduction of mean leakage area and central retinal thickness (CRT), respectively. Presence or recurrence of subretinal fluid (SRF), pigment epithelium detachment (PED) and retinal cysts were analyzed to decide for further injections and 12 eyes after loading regimen needed more injections. Autofluorescence variations were not significative in our group.
In our study we found intravitreal 0.5 mg ranibizumab effective in improving BCVA and retinal sensitivities during the first three months. Our data confirm that loading regimen is effective in reducing the progression of neovascular ARMD, but morphological analysis showed presence or recurrence of fluid in 60% of eyes those needed further injections during six-months follow-up.
This PDF is available to Subscribers Only